Back to results
US 11,896,717 B2Granted
Sustained-release dosage forms of ruxolitinib
AssigneesIncyte Holdings Corporation, Incyte Corporation
InventorsYong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Life of this patent
Estimating the term…
Abstract
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Claims23
An oral sustained release dosage form comprising:
- ruxolitinib phosphate, and
- a means for sustained release of the ruxolitinib phosphate,
- wherein the ruxolitinib phosphate is present in the dosage form in an amount ranging from 10 mg to 60 mg on a free base basis,
- wherein the dosage form is suitable for oral administration,
- wherein the administration of the dosage form results in a ratio of mean peak to plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h) of ruxolitinib of 10 or less, and
- wherein the administration of the dosage form to a human results in a mean half-life (t1/2) of from 3.5 hours to 11 hours.
3 more elements
Dependencies are inferred from the claim text.